America’s drug crisis isn’t a science problem; it’s a pricing and policy problem that blocks patients from medicines that already exist. In this episode, Dr. Jerry Avorn, a professor of medicine and leading expert in pharmacoepidemiology and medication policy, discusses why many patients still can’t afford essential treatments even as breakthrough drugs for cancer and inflammatory disease proliferate. He shares a personal case where “nonadherence” was really unaffordability, then unpacks how US exceptionalism in drug pricing, patent “thickets,” and delayed competition keep costs unsustainably high. Dr. Avorn also contrasts access failures with overuse concerns, explores why other countries negotiate on the basis of value, and addresses objections to innovation and rationing, including a sobering example of cystic fibrosis in the UK. Finally, he explains how academic detailing spreads evidence-based prescribing and evaluates recent US attempts to let Medicare negotiate prices alongside more deal-driven approaches. Tune in and learn how drug prices, patents, and public funding shape what patients can actually access! Resources: Connect with and follow Dr. Jerry Avorn on LinkedIn. Follow Harvard Medical School on LinkedIn and explore their website! Learn more about Brigham and Women’s Hospital on LinkedIn and visit their website. Visit Dr. Avorn’s personal website. Buy the Rethinking Meds book here and learn more about it here. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related